Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy

Digestive Diseases and Sciences

Volumn 61, Issue 2, 2016, Pages 371-380

  García Compeán, Diego ^a   González González, José Alberto ^a   Lavalle González, Fernando Javier ^a   González Moreno, Emmanuel Irineo ^a   Villarreal Pérez, Jesús Zacarías ^a   Maldonado Garza, Héctor J ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Chronic C hepatitis; Diabetes mellitus; Hepatogenous diabetes; Liver cirrhosis; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INTERLEUKIN 6; LEPTIN; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; SHORT ACTING INSULIN; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG SAFETY; GLUCOSE INTOLERANCE; HEPATITIS C; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; COMPLICATION; END STAGE LIVER DISEASE; HEPACIVIRUS; ISOLATION AND PURIFICATION; PATHOLOGY;

DIABETES MELLITUS; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84973486951     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3907-2     Document Type: Review

References (104)

1. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468.
2. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734–743.
3. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology. 2002;122:1822–1828.
4. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15:280–288.
5. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829–834.
6. Garcia-Compean D, Jaquez-Quintana JO, Lavalle-Gonzalez FJ, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis: A prospective study. Ann Hepatol. 2012;11:240–248.
7. Tappy L, Minehira K. New data and new concepts on the role of the liver in glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2001;4:273–277.
8. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: Prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology. 1998;28:141–149.
9. Petrides AS, Groop LC, Riely CA, DeFronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Investig. 1991;88:561–570.
10. Petrides AS, Vogt C, Schulze-berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 1994;19:616–627.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–S71.
12. Gundling F, Schepp W, Schumm-Draeger PM. Hepatogenous diabetes in cirrhosis: Academic sport or a neglected disease? Exp Clin Endocrinol Diabetes. 2012;120:469–471.
13. Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver. 1988;8:354–359.
14. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107–1119.
15. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract. 1990;8:29–36.
16. Matsumoto N, Arase Y, Seko Y, et al. Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL. Hepatol Res. 2012;42:558–563.
17. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race: A case–control study. Am J Gastroenterol. 2003;98:438–441.
18. Montenegro L, De Michina A, Misciagna G, Guerra V, Di Leo A. Virus C hepatitis and type 2 diabetes: A cohort study in southern Italy. Am J Gastroenterol. 2013;108:1108–1111.
19. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–599.
20. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075–7080.
21. Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection. Evidence for an association with type 2 diabetes. Diabetes Care. 2005;28:2548–2550.
22. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care. 2004;27:1171–1175.
23. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428–434.
24. Anty R, Gelsi E, Giudicelli J, et al. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. Eur J Gastroenterol Hepatol. 2007;19:671–677.
25. Custro N, Carroccio A, Ganci A, et al. Glicemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab. 2001;27:476–481.
26. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case–control study. Diabetes Care. 2006;29:1096–1101.
27. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–423.
28. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695–1704.
29. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5:26–34.
30. Antonelli A, Ferri C, Fallahi P, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2004;43:238–240.
31. Masini M, Campani D, Boggi U, et al. Hepatitis C virus infection and human pancreatic β-cell dysfunction. Diabetes Care. 2005;28:940–941.
32. Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823–831.
33. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–641.
34. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010;3:447–454.
35. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012;56:464–473.
36. Romero-Gómez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009;50:1702–1708.
37. Sanyal AJ, Chand N, Comar K, Mirshahi F. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: A potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic liver disease (Abstract). Hepatology. 2004;40:179A.
38. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:2462–2466.
39. Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: Results of a cohort study. Am J Gastroenterol. 2008;103:2481–2487.
40. Ruhl CE, Menke A, Cowie CC, Everhart JE. The relationship of hepatitis C virus infection with diabetes in the United States population. Hepatology. 2014;60:1139–1149.
41. Cusi K. The relationship between hepatitis C Virus infection and diabetes: Time for a Divorce? Hepatology. 2014;60:1121–1123.
42. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: Type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22:24–27.
43. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol. 2006;40:68–76.
44. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756–761.
45. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–125.
46. Quintana JO, García-Compean D, González JA, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis—A prospective study. Ann Hepatol. 2011;10:56–62.
47. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–681.
48. Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol. 2006;101:70–75.
49. García-Compeán D, Jáquez- Quintana JO, Lavalle-González FJ, et al. Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World J Gastroenterol. 2014;20:7011–7018.
50. Hagel S, Bruns T, Herrmann A, Stallmach A, Schmidt C. Abnormal glucose tolerance: A predictor of 30-day mortality in patients with decompensated liver cirrhosis. Z Gastroenterol. 2011;49:331–334.
51. Butt Z, Jadoon NA, Salaria ON, et al. Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in different age groups. J Diabetes. 2013;5:449–455.
52. Jeon HK, Kim MY, Baik SK, et al. Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage. Dig Dis Sci. 2013;58:3335–3341.
53. Huang YW, Wang TC, Lin SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study. Clin Infect Dis. 2013;57:1695–1702.
54. Hsiang JC, Gane EJ, Bai WW, Gerred SJ. Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J Gastroenterol Hepatol. 2015;30:591–599.
55. Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. Hepatology. 2012;55:1317–1323.
56. Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV related steatosis. Atherosclerosis. 2012;221:496–502.
57. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol. 2008;7:148–151.
58. Marchesini G, Ronchi M, Forlani G, et al. Cardiovascular disease in cirrhosis—A point-prevalence study in relation to glucose tolerance. Am J Gastroenterol. 1999;94:655–662.
59. An J, Shim JH, Kim SO, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: A registry-based matched case-control study. Circulation. 2014;130:1353–1362.
60. Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158–1163.
61. Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35:S10–S20.
62. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91–101.
63. García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, González-González JA, Maldonado-Garza HJ, Villarreal-Pérez JZ. Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study. Ann Hepatol. 2014;13:403–410.
64. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007;41:403–411.
65. Sorrentino P, Tarantino G, Conca P, Perrella A, Perella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. Can J Gastroenterol. 2004;18:381–386.
66. Ahmadieh H, Samir ST. Liver disease and diabetes: Association, pathophysiology and management. Diabetes Res Clin Pract. 2014;104:53–62.
67. Gundling F, Seidl H, Strassen I, et al. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion. 2013;87:75–84.
68. Kwon SY, Kim SS, Kwon OS, et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med. 2005;22:1530–1535.
69. Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3:33–40.
70. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011;96:2601–2608.
71. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014;60:2008–2016.
72. Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol. 2014;10:839–857.
73. Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin N Am. 1999;28:555–577.
74. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: Pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29:172–182.
75. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1082–1090.
76. de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:159–165.
77. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: A rare or very rare clinical entity? Diabet Med. 1999;16:273–281.
78. Edwards CM, Barton MA, Snook J, David M, Mak VH, Chowdhury TA. Metformin-associated lactic acidosis in a patient with liver disease. QJM. 2003;96:315–316.
79. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30:750–758.
80. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf. 2012;11:597–614.
81. Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci. 2002;47:1107–1110.
82. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol. 2000;40:634–640.
83. Scott LJ. Repaglinide: A review of its use in type 2 diabetes mellitus. Drugs. 2012;72:249–272.
84. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41:471–483.
85. Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol. 2004;19:480–487.
86. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815–821.
87. Ratziu V, Giral P, Jacqueminet S, LIDO Study Group, et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100–110.
88. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003;38:434–440.
89. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107–1115.
90. Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes:pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9:17–29.
91. Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J. 2012;2012:496453.
92. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81–99.
93. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74:75–85.
94. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:773–785.
95. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–514.
96. Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19:2298–2306.
97. Letiexhe MR, Scheen AJ, Gerard PL, et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab. 1993;77:1263–1268.
98. Petrides AS. Hepatogenic diabetes: Pathophysiology, therapeutic options and prognosis. Z Gastroenterol. 1999;16:15–21.
99. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469–476.
100. Kupčová V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr H. Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014;34:127–133.
101. Merli M, Leonetti F, Riggio O, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized alter liver transplantation. Hepatology. 1999;30:649–654.
102. Blanco JJ, Herrero JI, Quiroga J, et al. Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival, and adverse events. Liver Transpl. 2001;7:226–233.
103. Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. Hepatology. 2000;31:694–703.
104. Younossi ZM, Stepanova M, Saab S, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85,000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686–694.